ADMA Q3 2019 Earnings — ADMA Biologics, Inc. Revenue & Financial Results | Market Cap Arena

ADMAADMA Biologics, Inc.

$4B

Q3 2019 Earnings

Healthcare Biotechnology

Income Statement

Revenue

$7M+70.7% YoY

Gross Profit

-$693,717-9.6% margin

Operating Income

-$9M-125.3% margin

Net Income

-$11M-158.4% margin

EPS (Diluted)

$-0.19

QoQ Revenue Growth

+10.1%

Cash Flow

Operating Cash Flow

-$24M

Free Cash Flow

-$26M

Stock-Based Comp.

$650,670

Balance Sheet

Total Assets

$138M

Total Liabilities

$102M

Stockholders' Equity

$36M

Cash & Equivalents

$48M

Year-over-Year Comparison

Metric	Current	Year Ago	Change
Revenue	$7M	$4M	+70.7%
Gross Profit	-$693,717	-$5M	+85.9%
Operating Income	-$9M	-$14M	+34.4%
Net Income	-$11M	-$15M	+24.4%

Revenue Segments

ADMA BioManufacturing

$6M81%

Plasma Collection Centers

$1M18%

Corporate

$35,7080%